Update to Chronic Obstructive Pulmonary Disease (COPD) – Stable

25 Mar Update to Chronic Obstructive Pulmonary Disease (COPD) – Stable

All TreatGx users now have access to the updated treatment algorithm for Chronic Obstructive Pulmonary Disease (COPD) – Stable. As always, this update includes the TreatGx standard of providing personalized dosing based on any applicable pharmacogenetics, kidney function, liver function, and drug interactions.

This update was based on recent guidelines from GOLD 2022 [1], ATS 2020 [2], and VA/DoD 2021 [3]. This update involved simplification of medication options into 5 groups based on COPD Maintenance Treatment Strategy: Initiate maintenance therapy for GOLD Group A, B, C, D; or adjust maintenance therapy due to dyspnea and/or exacerbations. New medication options were added based on availability: revefenacin (US only), budesonide + glycopyrrolate/glycopyrronium + formoterol fumarate, and fluticasone furoate + umeclidinium + vilanterol.

References

1. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. 2022.
2. Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, Criner GJ, Donaldson GC, Dreher M, Fan VS et al: Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020, 201(9):e56-e69.
3. Department of Veterans Affairs/Department of Defense: VA/DoD Clinical Practice Guideline for the Management of Chronic Obstructive Pulmonary Disease. 2021.